Embolic Therapy for the Treatment of Liver Metastases

Reference work entry

Abstract

Transarterial therapies are playing a larger role for patients with unresectable metastatic disease to the liver. An understanding of treatment options, outcomes, and toxicities is important in a comprehensive treatment environment. The current review discusses existing treatment options including chemoembolization, embolization, and radioembolization. Additionally, outcomes with these different therapies are reviewed for a variety of metastatic processes to the liver. Disease states discussed include colorectal cancer, neuroendocrine tumors, breast cancer, and metastatic uveal melanoma. With each pathologic entity, the relative role of transarterial therapies both individually and as a group in comparison to other treatment methods such as resection and systemic chemotherapy is discussed. Expected side effects and toxicities from transarterial therapies in this diverse group of patients are reviewed as well.

Keywords

Ischemia Interferon Doxorubicin Sponge Bilirubin 

References

  1. 1.
    Stuart K. Chemoembolization in the management of liver tumors. Oncologist. 2003;8:425–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics. 2008;28:101–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Landry CS, Scoggins CR, McMasters KM, Martin 2nd RC. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol. 2008;97:253–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15:297–304.PubMedCrossRefGoogle Scholar
  9. 9.
    Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:8076–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Sato T, Eschelman DJ, Gonsalves CF, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26:5436–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969–77.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2006;17:225–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Gonsalves CF, Brown DB. Chemoembolization of hepatic malignancy. Abdom Imaging. 2009;34:557–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Gunven P. Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations. Med Oncol. 2008;25:1–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S211–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2009;20:S219–26, S26 e1–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9:261–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19:145–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17:1025–34.PubMedCrossRefGoogle Scholar
  20. 20.
    al-Bassam SH, Munk PL, Sallomi DF, et al. Chemo-embolization of hepatic tumours. Australas Radiol. 1999;43:165–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397–403.PubMedCrossRefGoogle Scholar
  22. 22.
    Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol. 1995;60:116–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004;15:1209–18.PubMedCrossRefGoogle Scholar
  24. 24.
    Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16:353–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol. 2002;13:1163–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Patel S, Tuite CM, Mondschein JI, Soulen MC. Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol. 2006;17:1931–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Reed RA, Teitelbaum GP, Daniels JR, Pentecost MJ, Katz MD. Prevalence of infection following hepatic chemoembolization with cross-linked collagen with administration of prophylactic antibiotics. J Vasc Interv Radiol. 1994;5:367–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol. 2004;15:547–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Arora R, Soulen MC, Haskal ZJ. Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol. 1999;10:1351–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Chung JW, Park JH, Han JK, Choi BI, Kim TK, Han MC. Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma: the safety and potential therapeutic role. J Vasc Interv Radiol. 1998;9:495–500.PubMedCrossRefGoogle Scholar
  31. 31.
    Tajima T, Honda H, Kuroiwa T, et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol. 2002;13:893–900.PubMedCrossRefGoogle Scholar
  32. 32.
    Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:321–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Chen MS, Li JQ, Zhang YQ, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol. 2002;8:74–8.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Higashi S, Tabata N, Kondo KH, et al. Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma. J Pharmacol Exp Ther. 1999;289:816–9.PubMedGoogle Scholar
  35. 35.
    Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 1987;60:1194–203.PubMedCrossRefGoogle Scholar
  36. 36.
    Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994;73:2259–67.PubMedCrossRefGoogle Scholar
  37. 37.
    Brown DB, Cai SR, Fundakowski CE, Zamboni WC, Strychor S, McLeod HL. Pharmacokinetics after endovascular lung perfusion with Cisplatin. J Vasc Interv Radiol. 2006;17:883–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Kubota K, Hisa N, Nishikawa T, et al. Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging. 2001;26:184–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000;175:699–704.PubMedCrossRefGoogle Scholar
  40. 40.
    Chopra S, Dodd 3rd GD, Chintapalli KN, Leyendecker JR, Karahan OI, Rhim H. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol. 2001;177:381–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol. 2006;17:1425–39.PubMedCrossRefGoogle Scholar
  42. 42.
    Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293–8.PubMedGoogle Scholar
  43. 43.
    Gunven P. Liver embolizations in oncology. A review. Part II. Arterial radioembolizations, portal venous embolizations, experimental arterial embolization procedures. Med Oncol. 2007;24:287–96.PubMedCrossRefGoogle Scholar
  44. 44.
    Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251–78.PubMedCrossRefGoogle Scholar
  45. 45.
    Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–47. discussion 47–50.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997;40:770–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Salman HS, Cynamon J, Jagust M, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer. 2002;2:173–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Lang EK, Brown Jr CL. Colorectal metastases to the liver: selective chemoembolization. Radiology. 1993;189:417–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Soulen MC. Chemoembolization of hepatic malignancies. Semin Interv Radiol. 1997;14:305–11.Google Scholar
  50. 50.
    Tellez C, Benson 3rd AB, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998;82:1250–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Martin RC, Joshi J, Robbins K, Tomalty D, O’Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. 2009;2009:539795.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo. 2007;21:1085–91.PubMedGoogle Scholar
  53. 53.
    Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer. 1994;74:1706–12.PubMedCrossRefGoogle Scholar
  54. 54.
    Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol. 2009;32:1179–86.PubMedCrossRefGoogle Scholar
  55. 55.
    Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187–95.PubMedCrossRefGoogle Scholar
  56. 56.
    Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571–93.PubMedCrossRefGoogle Scholar
  57. 57.
    Gray B, Van Hazel G. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–20.PubMedCrossRefGoogle Scholar
  58. 58.
    Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2010;117:343–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849–58.PubMedCrossRefGoogle Scholar
  60. 60.
    Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002;29:815–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45:1892–7.PubMedGoogle Scholar
  62. 62.
    Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992;62:105–10.PubMedCrossRefGoogle Scholar
  63. 63.
    Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–25.PubMedCrossRefGoogle Scholar
  64. 64.
    Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35:222–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18 F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 2005;16:1641–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85.PubMedCrossRefGoogle Scholar
  67. 67.
    Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099–1106.PubMedCrossRefGoogle Scholar
  68. 68.
    Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937–45.PubMedCrossRefGoogle Scholar
  69. 69.
    Chu QD, Hill HC, Douglass Jr HO, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9:855–62.PubMedCrossRefGoogle Scholar
  70. 70.
    Oberg K. Neuroendocrine gastrointestinal tumors–a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(Suppl 2):S3–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188:1201–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw. 2009;7:765–72.PubMedCrossRefGoogle Scholar
  73. 73.
    Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg. 1992;163:479–83.PubMedCrossRefGoogle Scholar
  74. 74.
    Pitt SC, Knuth J, Keily JM, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951–60.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol. 1953;39:368–76.PubMedCrossRefGoogle Scholar
  76. 76.
    Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83. discussion 83–5.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors–a retrospective single-center analysis. Digestion. 2003;68:94–101.PubMedCrossRefGoogle Scholar
  78. 78.
    Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.PubMedCrossRefGoogle Scholar
  79. 79.
    de Baere T, Deschamps F, Teriitheau C, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol. 2008;19:855–61.PubMedCrossRefGoogle Scholar
  80. 80.
    Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18:847–55.PubMedCrossRefGoogle Scholar
  82. 82.
    Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–35.PubMedCrossRefGoogle Scholar
  84. 84.
    King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Smith AR, Giusti R. The epidemiology of breast cancer. In: Bassett LW, Jackson V, Bralow L, editors. Diagnosis of diseases of the breast. Philadelphia: WB Saunders; 1997. p. 293–16.Google Scholar
  86. 86.
    Carty NJ, Foggitt A, Hamilton CR, Royle GT, Taylor I. Patterns of clinical metastasis in breast cancer: an analysis of 100 patients. Eur J Surg Oncol. 1995;21:607–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81:1109–12.PubMedCrossRefGoogle Scholar
  88. 88.
    Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5:773–82.PubMedCrossRefGoogle Scholar
  89. 89.
    Hoe AL, Royle GT, Taylor I. Breast liver metastases–incidence, diagnosis and outcome. J R Soc Med. 1991;84:714–6.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003;89:284–90.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007;18:957–63.PubMedCrossRefGoogle Scholar
  92. 92.
    Li XP, Meng ZQ, Guo WJ, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol. 2005;11:3782–7.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Vogl TJ, Naguib NN, Nour-Eldin NE, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol. 2010;20:173–80.PubMedCrossRefGoogle Scholar
  94. 94.
    Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology. 2003;229:457–64.PubMedCrossRefGoogle Scholar
  95. 95.
    Rubin D, Nutting C, Jones B. Metastatic breast cancer in a 54-year-old woman: integrative treatment with yttrium-90 radioembolization. Integr Cancer Ther. 2004;3:262–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Shields JA, Shields CL. Introduction to melanocytic tumors of the uvea. In: Shields JA, Shields CL, editors. Intraocular tumors: a text and atlas. Philadelphia: W.B. Saunders; 1992. p. 45–59.Google Scholar
  97. 97.
    Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639–43.PubMedCrossRefGoogle Scholar
  98. 98.
    Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665–70.PubMedCrossRefGoogle Scholar
  100. 100.
    Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74:e38–44.PubMedCrossRefGoogle Scholar
  101. 101.
    Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133:177–84.PubMedCrossRefGoogle Scholar
  102. 102.
    Fiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo. 2009;23:131–7.PubMedGoogle Scholar
  103. 103.
    Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20:S425–34.PubMedCrossRefGoogle Scholar
  104. 104.
    Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol. 2000;11:453–60.PubMedCrossRefGoogle Scholar
  105. 105.
    Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics. 1998;18:605–19.PubMedCrossRefGoogle Scholar
  106. 106.
    Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology. 1996;198:33–40.PubMedCrossRefGoogle Scholar
  107. 107.
    Ibukuro K, Tsukiyama T, Mori K, Inoue Y. Hepatic falciform ligament artery: angiographic anatomy and clinical importance. Surg Radiol Anat. 1998;20:367–71.PubMedCrossRefGoogle Scholar
  108. 108.
    Song SY, Chung JW, Lim HG, Park JH. Nonhepatic arteries originating from the hepatic arteries: angiographic analysis in 250 patients. J Vasc Interv Radiol. 2006;17:461–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–500.PubMedCrossRefGoogle Scholar
  110. 110.
    Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31:1237–48.PubMedCrossRefGoogle Scholar
  111. 111.
    Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538–46.PubMedCrossRefGoogle Scholar
  112. 112.
    Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.PubMedCrossRefGoogle Scholar
  113. 113.
    Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205–13.PubMedCrossRefGoogle Scholar
  114. 114.
    Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16:195–203.PubMedCrossRefGoogle Scholar
  115. 115.
    Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:965–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Diagnostic RadiologyThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Department of RadiologyThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations